Treatment of prostate cancer metastases: More than semantics

The Lancet

Volumn 379, Issue 9810, 2012, Pages 4-6

  Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; DENOSUMAB; OSTEOPONTIN;

BONE METASTASIS; BONE TURNOVER; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DISEASE FREE SURVIVAL; HUMAN; NOTE; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 84855477386     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61540-7     Document Type: Note

References (10)

1. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2011; published online Nov 16. DOI:10.1016/S0140-6736(11)61226-9.
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-64.
3. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008; 34: 92-101. (Pubitemid 351181016)
4. Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006; 12: 3361-67.
5. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-22.
6. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5: 21-28. (Pubitemid 40052322)
7. Loberg RD, Logothetis CJ, Keller ET, Pienta KH. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005; 23: 8232-41. (Pubitemid 46211560)
8. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 24: 9209-16. (Pubitemid 39665537)
9. McDermott RS, Deneux L, Mosseri V, et al. Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw 2002; 13: 121-27. (Pubitemid 34535582)
10. Efstathiou E, Titus M, Tsavachidou D, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2011; in press.